Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics

Akebia Therapeutics, Inc. (AKBA): $1.35

0.04 (-2.88%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add AKBA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#55 of 357

in industry

AKBA Price/Volume Stats

Current price $1.35 52-week high $1.84
Prev. close $1.39 52-week low $0.49
Day low $1.32 Volume 3,082,900
Day high $1.40 Avg. volume 2,101,473
50-day MA $1.43 Dividend yield N/A
200-day MA $1.22 Market Cap 268.48M

AKBA Stock Price Chart Interactive Chart >

AKBA POWR Grades

  • Value is the dimension where AKBA ranks best; there it ranks ahead of 88.32% of US stocks.
  • The strongest trend for AKBA is in Growth, which has been heading up over the past 26 weeks.
  • AKBA ranks lowest in Stability; there it ranks in the 10th percentile.

AKBA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AKBA is -4.91 -- better than just 2.86% of US stocks.
  • AKBA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.59% of US stocks.
  • With a year-over-year growth in debt of -45.32%, AKEBIA THERAPEUTICS INC's debt growth rate surpasses merely 6.28% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to AKEBIA THERAPEUTICS INC, a group of peers worth examining would be KPTI, INSG, GDDY, PRO, and AXDX.
  • AKBA's SEC filings can be seen here. And to visit AKEBIA THERAPEUTICS INC's official web site, go to www.akebia.com.

AKBA Valuation Summary

  • In comparison to the median Healthcare stock, AKBA's price/earnings ratio is 113.04% lower, now standing at -3.8.
  • AKBA's price/sales ratio has moved NA NA over the prior 119 months.

Below are key valuation metrics over time for AKBA.

Stock Date P/S P/B P/E EV/EBIT
AKBA 2023-12-29 1.2 -5.9 -3.8 -4.4
AKBA 2023-12-28 1.2 -6.1 -3.9 -4.5
AKBA 2023-12-27 1.2 -5.7 -3.7 -4.2
AKBA 2023-12-26 1.2 -5.7 -3.7 -4.2
AKBA 2023-12-22 1.2 -5.7 -3.7 -4.2
AKBA 2023-12-21 1.2 -5.7 -3.7 -4.2

AKBA Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -2.87%.
  • Its 3 year net cashflow from operations growth rate is now at 5.23%.
  • The 2 year cash and equivalents growth rate now stands at 51.3%.
AKBA's revenue has moved down $37,974,000 over the prior 33 months.

The table below shows AKBA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 297.027 -81.283 -155.688
2022-06-30 296.819 -171.358 -163.367
2022-03-31 222.973 -203.839 -275.681
2021-12-31 213.578 -252.965 -282.84
2021-09-30 210.672 -220.939 -299.162
2021-06-30 221.904 -191.906 -299.577

AKBA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AKBA has a Quality Grade of C, ranking ahead of 61.34% of graded US stocks.
  • AKBA's asset turnover comes in at 0.347 -- ranking 132nd of 682 Pharmaceutical Products stocks.
  • BPTH, ASLN, and ARDX are the stocks whose asset turnover ratios are most correlated with AKBA.

The table below shows AKBA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.347 0.186 -1.786
2021-03-31 0.385 -0.169 -2.192
2020-12-31 0.414 -0.002 -1.908
2020-09-30 0.414 0.121 -1.912
2020-06-30 0.439 0.181 -2.161
2020-03-31 0.442 0.596 -1.469

AKBA Price Target

For more insight on analysts targets of AKBA, see our AKBA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.54 Average Broker Recommendation 1.62 (Moderate Buy)

Akebia Therapeutics, Inc. (AKBA) Company Bio


Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.


AKBA Latest News Stream


Event/Time News Detail
Loading, please wait...

AKBA Latest Social Stream


Loading social stream, please wait...

View Full AKBA Social Stream

Latest AKBA News From Around the Web

Below are the latest news stories about AKEBIA THERAPEUTICS INC that investors may wish to consider to help them evaluate AKBA as an investment opportunity.

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.

Yahoo | December 20, 2023

Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year

It hasn't been the best quarter for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, since the share price has...

Yahoo | December 10, 2023

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia's common stock on November 30, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | December 1, 2023

Top Penny Stocks for Q4 2023

Top penny stocks this month include Myomo Inc., Expion360 Inc., and Akebia Therapeutics Inc., all of which have more than tripled in value this last year.

Yahoo | December 1, 2023

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST.

Yahoo | November 20, 2023

Read More 'AKBA' Stories Here

AKBA Price Returns

1-mo -16.67%
3-mo 36.34%
6-mo -12.34%
1-year 63.58%
3-year -61.10%
5-year -81.09%
YTD 8.87%
2023 114.90%
2022 -74.47%
2021 -19.29%
2020 -55.70%
2019 14.29%

Continue Researching AKBA

Here are a few links from around the web to help you further your research on Akebia Therapeutics Inc's stock as an investment opportunity:

Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq
Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!